Patents by Inventor Robert Narquizian

Robert Narquizian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080119486
    Abstract: The invention relates to compounds of formula wherein the substituents are described herein. The compounds may be used in the treatment of illnesses based on the glycine uptake inhibitor, such as psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.
    Type: Application
    Filed: October 31, 2007
    Publication date: May 22, 2008
    Inventors: Synese Jolidon, Robert Narquizian, Matthias Heinrich Nettekoven, Roger David Norcross, Emmanuel Pinard, Henri Stalder
  • Patent number: 7375226
    Abstract: The present invention relates to compounds of formula IA wherein R1, R2, R3, and n are as defined in the specification, and to pharmaceutically active acid addition salts thereof. The compounds of the invention are useful in the treatment of neurological and neuropsychiatric disorders.
    Type: Grant
    Filed: December 8, 2005
    Date of Patent: May 20, 2008
    Assignee: Hoffman-La Roche Inc.
    Inventors: Synese Jolidon, Robert Narquizian, Roger David Norcross, Emmanuel Pinard
  • Publication number: 20080076806
    Abstract: The present invention relates to compounds of formula I wherein R1, R2, R3, R4, R5, X, and n are as defined herein and the dotted line denotes an optional bond and pharmaceutically acceptable acid addition salts thereof. The compounds are useful in the treatment of neurological and neuropsychiatric disorders.
    Type: Application
    Filed: August 17, 2007
    Publication date: March 27, 2008
    Inventors: Synese Jolidon, Robert Narquizian, Emmanuel Pinard
  • Publication number: 20080058331
    Abstract: The present invention relates to compounds of formula I wherein R1, R2, R3, R4, and X are as defined herein or to pharmaceutically acceptable acid addition salts thereof, with the exception of 4-methoxy-N-[2-oxo-2-(phenylamino)ethyl]-N-phenyl-benzamide, 4-chloro-N-[2-[(4-methylphenyl)amino]-2-oxoethyl]-N-phenyl-benzamide, 4-chloro-N-[2-[5-chloro-2-methoxyphenyl)amino]-2-oxoethyl]-N-benzamide, 4-methyl-N-[2-oxo-2-[(2,4,6-trichlorophenyl)amino]ethyl]-N-benzamide, N-[2-[(4-methylphenyl)amino]-2-oxoethyl]-N-phenyl-benzamide, 4-methyl-N-[2-[(4-methylphenyl)amino]-2-oxoethyl]-N-phenyl-benzamide, 4-chloro-N-(2-oxo-2-[(2,4,6-trichlorophenyl)amino]ethyl]-N-benzamide and N-[2-[(2,4-dimethoxyphenyl)amino]-2-oxoethyl]-N-[(2-fluorophenyl)methyl]-benzeneacetamide. The compounds are useful in the treatment of neurological and neuropsychiatric disorders.
    Type: Application
    Filed: August 23, 2007
    Publication date: March 6, 2008
    Inventors: Synese Jolidon, Robert Narquizian, Emmanuel Pinard
  • Patent number: 7319099
    Abstract: The invention relates to compounds of formula wherein the substituents are described herein. The compounds may be used in the treatment of illnesses based on the glycine uptake inhibitor, such as psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.
    Type: Grant
    Filed: August 4, 2004
    Date of Patent: January 15, 2008
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Synese Jolidon, Robert Narquizian, Matthias Heinrich Nettekoven, Roger David Norcross, Emmanuel Pinard, Henri Stadler
  • Publication number: 20070299071
    Abstract: The present invention relates to compounds of formula I wherein R1, R2, R3, X, n, and m are as defined herein and to pharmaceutically acceptable acid addition salts thereof, to pharmaceutical compositions containing them, and to methods for treating neurological and neuropsychiatric disorders.
    Type: Application
    Filed: June 15, 2007
    Publication date: December 27, 2007
    Inventors: Synese Jolidon, Robert Narquizian, Roger Norcross, Emmanuel Pinard
  • Publication number: 20070275987
    Abstract: The invention is concerned with novel pyridopyrimidinone derivatives of formula (I): wherein R1 to R8, X, Y, m and n are as defined in the description and in the claims. The compounds of the present invention are HM74A agonists with improved properties compared to niacin and can be used for the treatment and/or prevention of diseases such as dyslipidemia, atherosclerosis, diabetes, metabolic syndrome, and other related diseases associated with HM74A.
    Type: Application
    Filed: May 11, 2007
    Publication date: November 29, 2007
    Inventors: Aurelia Conte, Henrietta Dehmlow, Uwe Grether, Nicole A. Kratochwil, Holger Kuehne, Robert Narquizian, Constantinos Panousis, Jens-Uwe Peters, Fabienne Ricklin, Stephan Roever
  • Patent number: 7294644
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, m and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors.
    Type: Grant
    Filed: December 22, 2003
    Date of Patent: November 13, 2007
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Alexander Mayweg, Hans Peter Marty, Werner Mueller, Robert Narquizian, Werner Neidhart, Philippe Pflieger, Stephan Roever
  • Publication number: 20070238754
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, m and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors.
    Type: Application
    Filed: May 10, 2007
    Publication date: October 11, 2007
    Inventors: Alexander Mayweg, Hans Marty, Werner Mueller, Robert Narquizian, Werner Neidhart, Philippe Pflieger, Stephan Roever
  • Publication number: 20070219207
    Abstract: The present invention relates to compounds of the general formula IC wherein R2, R?, R?, R3, R6, X1 and X1? are as defined herein and pharmaceutically active acid addition salts thereof. Compounds of the invention are useful for the treatment of neurological and neuropsychiatric disorders.
    Type: Application
    Filed: May 21, 2007
    Publication date: September 20, 2007
    Inventors: Synese Jolidon, Robert Narquizian, Roger Norcross, Emmanuel Pinard
  • Publication number: 20070213384
    Abstract: The present invention relates to compounds of formula I wherein R1, R2, R3, and R4 are as defined herein and to pharmaceutically acceptable acid addition salts thereof. Compounds of formula I or their tautomeric forms are good inhibitors of the glycine transporter 1 (GlyT-1), and have a good selectivity to glycine transporter 2 (GlyT-2) inhibitors. Such compounds are useful for the treatment of schizophrenia.
    Type: Application
    Filed: March 1, 2007
    Publication date: September 13, 2007
    Inventors: Synese Jolidon, Robert Narquizian, Roger Norcross, Emmanuel Pinard
  • Publication number: 20070161650
    Abstract: The invention is concerned with novel substituted thiophene derivatives of formula (I) wherein R1 to R8, X, m and n are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds are HM74A agonists and can be used as medicaments.
    Type: Application
    Filed: December 13, 2006
    Publication date: July 12, 2007
    Inventors: Henrietta Dehmlow, Uwe Grether, Nicole Kratochwil, Robert Narquizian, Constantinos Panousis
  • Patent number: 7241761
    Abstract: The present invention relates to compounds of the general formula I wherein R1 is the group and R2, R?, R?, R3, R4, R5, R6, R7, X1, X1?, X2, and N are as defined in the specification. Compounds of the invention are useful for the treatment of neurological and neuropsychiatric disorders.
    Type: Grant
    Filed: December 1, 2005
    Date of Patent: July 10, 2007
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Synese Jolidon, Robert Narquizian, Roger David Norcross, Emmanuel Pinard
  • Patent number: 7220744
    Abstract: The present invention relates to compounds of formula I wherein R1, R2, X1, and X2 are as defined in the specification and to pharmaceutically acceptable acid addition salts thereof. Such compounds are inhibitors of the glycine transporter 1 (GlyT-1) and can be used in the treatment of schizophrenia, cognitive impairment, and Alzheimer's disease.
    Type: Grant
    Filed: January 3, 2006
    Date of Patent: May 22, 2007
    Assignee: Hoffman-La Roche Inc.
    Inventors: Synese Jolidon, Robert Narquizian, Roger David Norcross, Emmanuel Pinard
  • Publication number: 20070072873
    Abstract: The invention is concerned with novel substituted thiophene derivatives of formula (I) wherein R1 to R8, X, m and n are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds are HM74A agonists and can be used as medicaments.
    Type: Application
    Filed: September 20, 2006
    Publication date: March 29, 2007
    Inventors: Henrietta Dehmlow, Uwe Grether, Nicole Kratochwil, Robert Narquizian, Constantinos Panousis
  • Publication number: 20060281810
    Abstract: The invention is concerned with novel anthranilic acid derivatives of formula (I) wherein R1 to R14 and n are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds are HM74A agonists and can be used as medicaments.
    Type: Application
    Filed: June 12, 2006
    Publication date: December 14, 2006
    Inventors: Henrietta Dehmlow, Uwe Grether, Nicole Kratochwil, Robert Narquizian, Constantinos Panousis, Jens-Uwe Peters
  • Patent number: 7135488
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6 and R7 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors.
    Type: Grant
    Filed: December 22, 2003
    Date of Patent: November 14, 2006
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Wolgang Guba, Wolfgang Haap, Hans Peter Marty, Robert Narquizian
  • Patent number: 7122555
    Abstract: The present invention provides compounds of formula (I) wherein R1, R2, R3 and R4 are as indicated in the description, or a pharmaceutically acceptable salt thereof. The compounds are useful for the treatment of diseases which are associated with DPP-IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.
    Type: Grant
    Filed: June 17, 2004
    Date of Patent: October 17, 2006
    Assignee: Hoffmann-la Roche Inc.
    Inventors: Markus Boehringer, Bernd Kuhn, Patrizio Mattei, Robert Narquizian
  • Publication number: 20060178381
    Abstract: The present invention relates to compounds of formula I wherein R1, R2, and are defined in the specification and to pharmaceutically acceptable acid addition salts thereof.
    Type: Application
    Filed: January 31, 2006
    Publication date: August 10, 2006
    Inventors: Synese Jolidon, Robert Narquizian, Roger Norcross, Emmanuel Pinard
  • Publication number: 20060167023
    Abstract: The present invention relates to compounds of general formula IA or IB wherein X1 and X2 are each independently N or C—R? and R1, R2,R3, R4, R5, and R6 are as defined in the specification and to pharmaceutically acceptable acid addition salts thereof. The compounds can be used for the treatment of diseases related to the glycine transporter inhibitor, such as schizophrenia and Alzheimer's disease.
    Type: Application
    Filed: January 24, 2006
    Publication date: July 27, 2006
    Inventors: Synese Jolidon, Robert Narquizian, Roger Norcross, Emmanuel Pinard